| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Here we show that systemic administration of liraglutide, a long-acting human glucagon-like peptide-1 (GLP-1) analog, significantly decreased food
intake, body weight, and blood glucose levels at 24 h after its administration in individually housed KKAy mice. In addition, the systemic administration of liraglutide significantly increased plasma fibroblast growth factor (Fgf) 21 levels associated with increases in the expression of hepatic Fgf21, while having no effects on the expression of Fgf21 in white adipose tissue. Despite remarkably increased plasma active GLP-1 levels, the ingestion of alogliptin, a selective dipeptidyl peptidase-4 inhibitor, had no effects on food intake, body weight, blood glucose levels, and plasma Fgf21 levels. These findings suggest that systemic administration of liraglutide induces hepatic Fgf21 production and suppresses the social isolation-induced obesity and diabetes independently of insulin, glucagon, and active GLP-1 in KKAy mice.
|
